Abstract 4273
Background
Lung cancer is the main cause of cancer-related death worldwide. Epithelial-mesenchymal transition (EMT) is one of the major molecular mechanisms inducing tumor invasion and metastasis. Paired-related homeobox 1 (Prrx1) is a newly found EMT-inducing transcription factor. The prognostic value of Prrx1 in lung cancer has not been well demonstrated.
Methods
H1299-Prrx1 cell lines were generated by transfecting the pcDNA3.1-Prrx1 plasmid into H1299 cells. The H1299-Prrx1-Twisti cell lines were generated by transfecting the pSUPER-Twisti plasmid into H1299-Prrx1 cells. Immunofluorescence staining was done to demonstrate expression of E-cadherin and vimentin in these cells. Soft agar clonogenicity assay was done in these cell lines to demonstrate anchorage-independent growth. Cell migration and invasiveness assay were done in these cells to demonstrate their invasion and migration ability. In vivo tail vein metastasis assay was done to demonstrate the ability of Prrx1 overexpression in metastasis in vivo. Immunohistochemistry analysis of Prrx1 expression was done in 110 specimens of lung cancer patients.
Results
Prrx1 overexpression increased transformation activity, induced EMT and increased migration/invasiveness of H1299 cells. Prrx1 overexpression also increased metastatic ability in vivo. Prrx1 overexpression upregulated the expression of Twist and its downstream target matrix metalloproteinase 1 (MMP1). EMT phenotypes, increased migration/invasiveness of H1299-Prrx1 cells, and increase MMP1 expression were reversed by siRNA-mediated repression of Twist expression or a phosphatidylinositol (PI) 3-kinase inhibitor. Prrx1 overexpression predicted lower recurrence-free survival in patients with lung adenocarcinoma.
Conclusions
Prrx1 overexpression induces EMT through upregulation of PI 3-kinase/Akt/Twist/MMP1 axis. Prrx1 overexpression also predicts recurrence in lung cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3930 - Safety profile of tepotinib in patients with advanced solid tumors: pooled analysis of phase I and II data
Presenter: Thomas Decaens
Session: Poster Display session 1
Resources:
Abstract
5373 - Drug-drug interaction profile of tepotinib with CYP3A and P-gp substrates
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
5455 - Bioavailability of tepotinib: impact of omeprazole and food
Presenter: Juergen Heuer
Session: Poster Display session 1
Resources:
Abstract
2618 - Tislelizumab Exposure-Response Analyses of Efficacy and Safety in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2563 - Population Pharmacokinetics of Tislelizumab in Patients with Advanced Tumors
Presenter: Chi-Yuan Wu
Session: Poster Display session 1
Resources:
Abstract
2021 - The Addition of Metformin to Systemic Anticancer Therapy
Presenter: Jung Han Kim
Session: Poster Display session 1
Resources:
Abstract
5243 - Growth modulation index (GMI) as a comparative measure of clinical activity of larotrectinib versus prior systemic treatments in adult and pediatric TRK fusion cancer patients
Presenter: Antoine Italiano
Session: Poster Display session 1
Resources:
Abstract
598 - Analysis of the overall survival and main surrogates used for FDA approvals in solid and hematological malignancies.
Presenter: Maria Kleniewska-Wieczor
Session: Poster Display session 1
Resources:
Abstract
5381 - Comparison of intratumoral docetaxel exposure in cancer patients between nanoparticle entrapped docetaxel (CPC634) and conventional docetaxel (Cd): the CriTax study
Presenter: Ruben Van Eerden
Session: Poster Display session 1
Resources:
Abstract
2935 - Correlation of progression free survival-2 and overall survival in solid tumors
Presenter: Paul Mainwaring
Session: Poster Display session 1
Resources:
Abstract